Nine-TZ Home | Company | Services | People | Assignments | O-Zone | News | Contact Us

Nine-TZ

The O-Zone

Sunday 5th September 2010

The O-Zone

Welcome To The O-Zone ™

An occasional series in which guest authors share their opinions on matters that affect our industry

We welcome comments and suggestions for O-Zone articles. If you are interested in contributing to the O-Zone
click here.

Search Articles

Browse By Categories

Industry

Total Articles: 7
Latest Post: What Price Good Health?

Browse By Author

Chris O’Toole

Chris O’Toole

Total Articles: 1
Latest Post: What Price Good Health?
View All Posts

David Cavalla

Total Articles: 1
Latest Post: Glivec™: a new therapeutic opportunity for diabetes?
View All Posts

Total Articles: 1
Latest Post: Why industry should join the party
View All Posts

James Greenwood

James Greenwood

Total Articles: 1
Latest Post: Expanding Patients' Access to Biologic Medicines is Crucial
View All Posts

Martin Joseph

Total Articles: 1
Latest Post: Project Assassins and Champions
View All Posts

Michael Milken

Total Articles: 1
Latest Post: Health Reform
View All Posts

Rockport Venture Partners

Rockport Venture Partners

Total Articles: 1
Latest Post: Why the Time is Ripe for Private Equity Investment in Healthcare
View All Posts

Viewing Articles By David Cavalla

Viewing Articles By David Cavalla

O-Zone » David Cavalla

Total Articles: 1
Company: Numedicus Limited

Glivec™: a new therapeutic opportunity for diabetes?

Glivec™: a new therapeutic opportunity for diabetes?

Date: 2nd Jun 2009 | Category: Industry | Author: David Cavalla

Finding a new indication for an existing drug (or a developmental one) has been the basis for a good number of medicines over decades, from Viagra™ to thalidomide (Thalidomid), often by serendipity. Recently it been advocated as a strategic means of enhancing R&D efficiency, through its combined allure of reduced risk of failure, time and cost of new product entry.